XFOR News and Press, X4 Pharmaceuticals Inc. From 12/09/23

Initial data continue to support advancement of mavorixafor into pivotal, global Phase 3 trial in certain chronic neutropenic disorders; company on track to initiate in 1H 2024 X4 expects to present additional CN Phase 2 clinical trial data in 1H 2024 BOSTON, Dec. 09, 2023 (GLOBE ...

BOSTON, Nov. 10, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in fireside chats at the upcoming Stifel Healthcare Conference being ...

2023-11-09 12:37:01 ET X4 Pharmaceuticals, Inc. (XFOR) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Dan Ferry – LifeSci Advisors Paula Ragan – Chief Executive Officer Mark Baldry – Chief Commercial Officer...

2023-11-09 06:06:07 ET More on X4 Pharmaceuticals X4: De-Risking By WHIM Indication, Promising Potential For Expansion To Larger Market X4 Pharmaceuticals says CEO Paula Ragan sells 239.4K shares X4 shares jump as FDA accepts priority review of pediatric WHIM drug ...

U.S. New Drug Application for mavorixafor in WHIM syndrome accepted for Priority Review, establishing a PDUFA target action date of April 30, 2024; X4 eligible to receive Priority Review Voucher if approved Presentations of additional data from ongoing Phase 2 clinical trial of mavori...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

X4 Pharmaceuticals Inc. (XFOR) is expected to report $-0.15 for Q3 2023

2023-11-06 12:12:03 ET More on X4 Pharmaceuticals X4: De-Risking By WHIM Indication, Promising Potential For Expansion To Larger Market X4 submits New Drug Application to FDA for WHIM syndrome drug Seeking Alpha’s Quant Rating on X4 Pharmaceuticals For...

BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the third quarter ended September 30, 2023 and provid...

2023-10-31 10:35:43 ET More on X4 Pharmaceuticals X4: De-Risking By WHIM Indication, Promising Potential For Expansion To Larger Market X4 Pharmaceuticals, Inc. (XFOR) Q2 2023 Earnings Call Transcript X4 submits New Drug Application to FDA for WHIM syndrome drug ...